verified — Trust Score 100/100
This post is fully verified. It accurately describes the development of Anktiva by Patrick Soon-Shiong, its mechanism of activating natural killer cells, and its regulatory milestones. The claim that Saudi Arabia became the first country to approve it for lung cancer in January 2026 is confirmed by official statements from ImmunityBio and the Saudi Press Agency.
- Platform
- Source author
- mindset.therapy
- Original post
- https://www.instagram.com/p/DXXvlNAjpnY/?igsh=MTB0d3JkNGk5YjFuaA==
- Verified on
- April 21, 2026
- Verification ID
- zy52LOJY14ZfiLqwb3K1ig
Original content reviewed
Platform: INSTAGRAM Author: @mindset.therapy --- Caption/Description --- A new cancer treatment developed by Patrick Soon Shiong is gaining attention for how it works with the body instead of against it. The approach, called Anktiva, activates natural killer cells, a type of immune cell that identifies and destroys abnormal cells including cancer. Natural killer cell based therapies are part of a broader field called immunotherapy. Research shows these cells can detect and attack cancer without prior exposure, making them a powerful early defense. Anktiva is currently approved in the United States for a specific type of bladder cancer. In January 2026, Saudi Arabia became the first country in the world to approve it for lung cancer as well, going further than the U.S. FDA. Ongoing trials will determine its long term impact, but it reflects a growing shift toward treatments that support the body’s own immune system. #cancerresearch #immunotherapy #healthinnovation #medicalscience #awareness --- On-Screen Text (OCR) --- PATRICK SOON SHIONG HAS DEVELOPED A TREATMENT THAT TURNS ON THE BODY'S NATURAL KILLER CELLS TO TARGET CANCER CELLS. IT IS APPROVED IN THE U.S., AND SAUDI ARABIA HAS NOW CLEARED IT FOR PUBLIC USE. Published: 2026-04-20T22:56:02.000Z ---VERIFICATION_SUMMARY--- Platform: INSTAGRAM Author: @mindset.therapy --- Caption/Description --- A new cancer treatment developed by Patrick Soon Shiong is gaining attention for how it works with the body instead of against it. The approach, called Anktiva, activates natural killer cells, a type of immune cell that identifies and destroys abnormal cells including cancer. Natural killer cell based therapies are part of a broader field called immunotherapy. Research shows these cells can detect and attack cancer without prior exposure, making them a powerful early defense. Anktiva is currently approved in the United States for a specific type of bladder cancer. In January 2026, Saudi Arabia became the first c
Claims analyzed (4)
- verified: Patrick Soon-Shiong developed a cancer treatment called Anktiva.
Patrick Soon-Shiong is the founder and Executive Chairman of ImmunityBio, the company that developed and manufactures Anktiva (N-803). - verified: Anktiva activates natural killer (NK) cells to target cancer.
Anktiva is an IL-15 receptor agonist designed to proliferate and activate NK cells and CD8+ killer T cells. - verified: Anktiva is approved in the U.S. for a specific type of bladder cancer.
The FDA approved Anktiva in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). - verified: In January 2026, Saudi Arabia became the first country to approve Anktiva for lung cancer.
The Saudi Food and Drug Authority (SFDA) granted accelerated approval for Anktiva for metastatic non-small cell lung cancer on January 14, 2026, marking a global first for this indication.
Sources consulted (8)
- oncodaily.com — oncodaily.com
- ImmunityBio Announces FDA Approval of ANKTIVA — ImmunityBio
- Patrick Soon-Shiong's cancer drug Anktiva approved by Saudi Arabia FDA — NewsNation (CUOMO)
- Anktiva as a lymphocyte rescue molecule: Unlocking the power of NK cells and T cells — Urology Times
- Mechanisms of natural killer cell-mediated cellular cytotoxicity — PubMed (NIH)
- Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA for Metastatic Non-Small Cell Lung Cancer — ImmunityBio
- SFDA Approves Registration of 'Anktiva' for Treatment of Bladder and Lung Cancer — Saudi Press Agency
- Natural killer cells in clinical development — PMC (NIH)
Related verifications
- mostly true — Trust Score 85/100instagram · view post ↗
The claims regarding ginger's benefits for menstrual health are, including multiple peer-reviewed clinical trials and meta-analyses. While the image is AI-generated and the 'two-week' protocol is a si…
- mostly true — Trust Score 79/100instagram · view post ↗
This post is an authentic statement from Dr. Mike Banna (@drmikethe2nd) posted on January 19, 2026. His claims regarding the cost and nutritional profile of the viral 'yogurt cheesecake' hack are, as …
- verified — Trust Score 92/100instagram · view post ↗
The claims in this post are confirmed by 3 sources, including a landmark 2025 study in Nature Aging and multiple 2023-2026 clinical reviews. While the ranking is the author's synthesis, it accurately …
- mostly true — Trust Score 75/100instagram · view post ↗
The core health claim is confirmed by 6 sources including Harvard Health and the National Institutes of Health, based on a long-term study of over 30,000 men. However, the post is mostly true rather t…
- mostly true — Trust Score 65/100instagram · view post ↗
The health and lifestyle claims in this post reported by the NIH and Mayo Clinic, though some are simplified for marketing. However, the post is a high-pressure sales funnel for a coaching program wit…
AI-generated analysis. Not a substitute for professional fact-checking.